Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sasha Sutherland

Internal Medicine Tampa, FL Medical Doctor

NPI 1396914651 CMS profile 17693

10330 N Dale Mabry Hwy, Suite 190, Tampa, FL 33618

Open in the dashboard

General payments

$6,874

341 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sasha Sutherland of Tampa, FL is reported in the CMS Open Payments database as having received $6,874 across 341 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,703 81
2024 General $1,665 81
2023 General $1,019 45
2022 General $501 30
2021 General $560 24
2020 General $530 26
2019 General $895 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sasha Sutherland
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sasha Sutherland were reported at $1,703. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sasha Sutherland Internal Medicine median Middle half National median
2019 $895 $159 $48–$570 $163
2020 $530 $119 $33–$402 $114
2021 $560 $135 $37–$521 $132
2022 $501 $141 $42–$496 $149
2023 $1,019 $149 $45–$519 $160
2024 $1,665 $154 $47–$537 $164
2025 $1,703 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,334 69 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $996 44 payments
  3. AstraZeneca Pharmaceuticals LP $631 36 payments
  4. Pfizer Inc. $458 28 payments
  5. Amgen Inc. $397 24 payments
  6. Lilly USA, LLC $382 26 payments
  7. Lucid Diagnostics Inc. $277 14 payments
  8. Exact Sciences Corporation $252 12 payments
  9. GlaxoSmithKline, LLC. $237 9 payments
  10. Dynavax Technologies Corporation $230 9 payments
  11. Other $1,680 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,866 340 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $777 44 payments
  2. JARDIANCE $768 33 payments
  3. RYBELSUS $759 37 payments
  4. AIRSUPRA $280 15 payments
  5. Otezla $277 20 payments
  6. Cologuard Collection Kit $252 12 payments
  7. FARXIGA $249 16 payments
  8. SYNJARDY $249 11 payments
  9. Heplisav-B $230 9 payments
  10. TRADJENTA $222 11 payments
  11. Other $4,912 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 92 drugs

Part D claims

4,761

Median for Internal Medicine: 777

Drug cost

$464,271

Median for Internal Medicine: $73,373

Branded share of claims

21.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 139 $130,364
Ozempic Semaglutide Brand 49 $58,455
Rybelsus Semaglutide Brand 39 $52,155
Mounjaro Tirzepatide Brand 29 $30,200
Trulicity Dulaglutide Brand 21 $26,904
Eliquis Apixaban Brand 31 $25,328
Farxiga Dapagliflozin Propanediol Brand 21 $22,113
Januvia Sitagliptin Phosphate Brand 21 $16,767
Vascepa Icosapent Ethyl Brand 21 $15,646
Linzess Linaclotide Brand 13 $7,495

The 10 drugs with the highest cost, of 92 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$69,822

Of which drugs: $9,897

Medicare patients

154

Average age 73

Services billed

826

114 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 41%
Diabetes 38%
Chronic kidney disease 31%
Depression 29%
Osteoporosis 21%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 21 21 $6,088
Vaccine for influenza for injection into muscle 90662 Office 36 36 $2,886

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Heplisav-B
  • Dynavax Technologies Corporation $123
$123 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $120
$120 — —
Korlym
  • Corcept Therapeutics $115
$115 — —
Wegovy
  • Novo Nordisk Inc $104
$104 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $104
$104 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record